BeiGene's revenue for the
three
months ended in Dec. 2023 was $634 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $2,459 Mil.
BeiGene's Revenue per Share for the
three
months ended in Dec. 2023 was $6.10.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $23.39.
During the past 12 months, the average Revenue per Share Growth Rate of BeiGene was 71.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 85.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 43.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 73.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 11 years, BeiGene's highest 3-Year average Revenue per Share Growth Rate was 494.10% per year. The lowest was -45.70% per year. And the median was 68.90% per year.
BeiGene Revenue Historical Data
The historical data trend for BeiGene's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BeiGene's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeiGene Revenue Distribution
For the Biotechnology industry and Healthcare sector, BeiGene's Revenue distribution charts can be found below:
* The bar in red indicates where BeiGene's Revenue falls into.
BeiGene Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,459 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeiGene (NAS:BGNE) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BeiGene Revenue Related Terms
Thank you for viewing the detailed overview of BeiGene's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGNE has been successfully added to your 